Silicate esters of paclitaxel and docetaxel: Synthesis, hydrophobicity, hydrolytic stability, cytotoxicity, and prodrug potential

Journal of Medicinal Chemistry

Volumn 57, Issue 6, 2014, Pages 2368-2379

  Wohl, Adam R ^a   Michel, Andrew R ^a   Kalscheuer, Stephen ^b   Macosko, Christopher W ^a   Panyam, Jayanth ^b   Hoye, Thomas R ^a  

^a University of Minnesota   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 O [(TRI N OCTYLOXY) SILYL] PACLITAXEL; 2' (DI TERT BUTOXYETHOXYSILYL) DOCETAXEL; 2' (TRIMENTHYLOXYSILYLOXY) DOCETAXEL; 2' O ((DI TERT BUTOXY) (ETHOXY) SILYL) PACLITAXEL; 2' O (DI TERT BUTOXYACETOXYSILYL) PACLITAXEL; 2' O (TRI N OCTYLOXYSILYL) DOCETAXEL; 2' O (TRIETHOXYSILYL) DOCETAXEL; 2' O (TRIISOPROPOXYSILYL) DOCETAXEL; 2' O [(TRI TERT BUTOXY) SILYL] PACLITAXEL; 2' O [(TRIETHOXY) SILYL] PACLITAXEL; 2' O [(TRIISOPROPOXY) SILYL] PACLITAXEL; 2' [(TRIMENTHYLOXY) SILYL] PACLITAXEL; 2',7 DI O (TRIETHOXYSILYL) PACLITAXEL; 2',7' DI O (TRIISOPROPOXYSILYL) PACLITAXEL; 2,7' DI O (TRI N OCTYLOXYSILYL) PACLITAXEL; 7 0 (TRI N OCTYLOXYSILYL) PACLITAXEL; 7 O (TRI N OCTYLOXYSILYL) PACLITAXEL; 7 O (TRIETHOXYSILYL) PACLITAXEL; ALKYL GROUP; DOCETAXEL; ESTER DERIVATIVE; PACLITAXEL; PRODRUG; SILICATE; TETRAALKOXYSILANE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG HYDROLYSIS; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; IN VITRO STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE; CELL SURVIVAL; COLORING AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; HYDROLYSIS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INDICATORS AND REAGENTS; KINETICS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NANOPARTICLES; PACLITAXEL; PRODRUGS; SILICATES; TAXOIDS; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84897390232     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401708f     Document Type: Article

References (40)

1. Ismael, G. F. V.; Rosa, D. D.; Mano, M. S.; Awada, A. Novel cytotoxic drugs: old challenges, new solutions Cancer Treat. Rev. 2008, 34, 81-91
2. Hennenfent, K. L.; Govindan, R. New formulations of taxanes: a review. Old wine in a new bottle? Ann. Oncol. 2006, 17, 735-749
3. Johnson, B. K.; Prud'homme, R. K. Chemical processing and micromixing in confined impinging jets AIChE J. 2003, 49, 2264-2282
4. Johnson, B. K.; Prud'homme, R. K. Flash nanoprecipitation of organic actives and block copolymers using a confined impinging jets mixer Aust. J. Chem. 2003, 56, 1021-1024
5. Han, J.; Zhu, Z.; Qian, H.; Wohl, A. R.; Beaman, C. J.; Hoye, T. R.; Macosko, C. W. A simple confined impingement jets mixer for flash nanoprecipitation J. Pharm. Sci. 2012, 101, 4018-4023
6. Pustulka, K. M.; Wohl, A. R.; Lee, H. S.; Michel, A. R.; Han, J.; Hoye, T. R.; McCormick, A. V.; Panyam, J.; Macosko, C. W. Flash nanoprecipitation: particle structure and stability Mol. Pharmaceutics 2013, 10, 4367-4377
7. Saad, W. S. Drug nanoparticle formation via flash nanoprecipitation: conjugation to encapsulate and control the release of paclitaxel. Ph.D. Thesis, Princeton University, Princeton, NJ, 2007.
8. Zhu, Z. Polymer stabilized nanoparticles via flash nanoprecipitation: particle formation, formulation, and stability. Ph.D. Thesis, University of Minnesota, Minneapolis, MN, 2010.
9. Corriu, R. J. P.; Granier, M.; Lanneau, G. F. Synthesis and reactivity of bis(triethoxysilyl)methane, tris(triethoxysilyl)methane and some derivatives J. Organomet. Chem. 1998, 562, 79-88
10. Hoye, T. R.; Wohl, A. W.; Macosko, C. W.; Panyam, J. Silicate prodrugs and nanoparticles. U.S. Patent Application PCT/US2012/040247, May 31, 2012.
11. Gitelman, H. J.; Alderman, F.; Perry, S. J. Renal handling of silicon in normals and patients with renal insufficiency Kidney Int. 1992, 42, 957-959
12. Marco-Franco, J. E.; Torres, V. E.; Nixon, D. E.; Wilson, D. M.; James, E. M.; Bergstrahl, E. J.; McCarthy, J. T. Oxalate, silicon, and vanadium in acquired cystic kidney disease Clin. Nephrol. 1991, 35, 52-58
13. Anglin, E. J.; Cheng, L.; Freeman, W. R.; Sailor, M. J. Porous silicon in drug delivery devices and materials Adv. Drug Delivery Rev. 2008, 60, 1266-1277
14. Parrott, M. C.; Finniss, M.; Luft, J. C.; Pandya, A.; Gullapalli, A.; Napier, M. E.; DeSimone, J. M. Incorporation and controlled release of silyl ether prodrugs from PRINT nanoparticles J. Am. Chem. Soc. 2012, 134, 7978-7982
15. Skwarczynski, M.; Hayashi, Y.; Kiso, Y. Paclitaxel prodrugs: toward smarter delivery of anticancer agents J. Med. Chem. 2006, 49, 7253-7269
16. Vyas, D. M.; Wong, H.; Crosswell, A. R.; Casazza, A. M.; Knipe, J. O.; Mamber, S. W.; Doyle, T. W. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel Bioorg. Med. Chem. Lett. 1993, 3, 1357-1360
17. Moosavi-Movahedi, A. A.; Hakimelahi, S.; Chamani, J.; Khodarahmi, G. A.; Hassanzadeh, F.; Luo, F. T.; Ly, T. W.; Shia, K.-S.; Yen, C. F.; Jain, M. L.; Kulatheeswaran, R.; Xue, C.; Pasdar, M.; Hakimelahi, G. H. Design, synthesis, and anticancer activity of phosphonic acid diphosphate derivative of adenine-containing butenolide and its water soluble derivatives of paclitaxel with high antitumor activity Bioorg. Med. Chem. 2003, 11, 4303-4313
18. Paradis, R.; Page, M. New active paclitaxel amino acid derivatives with improved water solubility Anticancer Res. 1998, 18, 2711-2716
19. Deutsch, H. M.; Glinski, J. A.; Hernandez, M.; Haugwitz, R. D.; Narayanan, V. L.; Suffness, M.; Zalkow, L. H. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of Taxol with potent antitumor activity J. Med. Chem. 1989, 32, 788-792
20. Khmelnitsky, Y. L.; Budde, C.; Arnold, M. J.; Usyatinsky, A.; Clark, D. S.; Dordick, J. S. Synthesis of water-soluble paclitaxel derivatives by enzymatic acylation J. Am. Chem. Soc. 1997, 119, 11554-11555
21. Stevens, P. J.; Sekido, M.; Lee, R. J. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug Pharm. Res. 2004, 21, 2153-2157
22. Ansell, S. Lipophilic drug derivatives for use in liposomes. U.S. Patent 5,534,499, July 9, 1996.
23. Lundberg, B. B.; Risovic, V.; Ramaswamy, M.; Wasan, K. M. A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration J. Controlled Release 2003, 86, 93-100
24. Rodrigues, D. C.; Maria, D. A.; Fernandes, D. C.; Valduga, C. J.; Couto, R. D.; Ibanez, O. C. M.; Maranhao, R. C. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies Cancer Chemother. Pharmacol. 2005, 55, 565-576
25. Ansell, S. M.; Johnstone, S. A.; Tardi, P. G.; Lo, L.; Xie, S.; Shu, Y.; Harasym, T. O.; Harasym, N. L.; Williams, L.; Bermudes, D.; Liboiron, B. D.; Saad, W.; Prud'homme, R. K.; Mayer, L. D. Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates J. Med. Chem. 2008, 51, 3288-3296
26. Petros, R. A.; DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications Nat. Rev. Drug Discovery 2010, 9, 615-627
27. Wang, A. Z.; Langer, R.; Farokhzad, O. C. Nanoparticle delivery of cancer drugs Annu. Rev. Med. 2012, 63, 185-198
28. Bradley, M. O.; Webb, N. L.; Anthony, F. H.; Devanesan, P.; Witman, P. A.; Hemamalini, S.; Chander, M. C.; Baker, S. D.; He, L.; Horwitz, S. B.; Swindell, C. S. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel Clin. Cancer Res. 2001, 7, 3229-3238
29. Bedikian, A. Y.; DeConti, R. C.; Conry, R.; Agarwala, S.; Papadopoulos, N.; Kim, K. B.; Ernstoff, M. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma Ann. Oncol. 2011, 22, 787-793
30. Kingston, D. G. I. Taxol, a molecule for all seasons Chem. Commun. 2001, 37, 867-880
31. Gerrard, W.; Howe, B. K. The behaviour of 1,1,1,3,3,3-hexachloropropan-2- ol with inorganic non-metal halides J. Chem. Soc. 1955, 505-510
32. Chappelow, C. C.; Elliot, R. L.; Goodwin, J. T. The phenylation and methylation of alkoxychlorosilanes J. Org. Chem. 1960, 25, 435-439
33. Beckman, J.; Daketernieks, D.; Tiekink, E. R. T. Chiral trialkoxysilanols derived from terpene alcohols. Molecular structures of tris([(1 S)- endo ]-(-)-bornoxy)silanol and tetrakis((-)-menthoxy)silane J. Organomet. Chem. 2002, 648, 188-192
34. Gerrard, W.; Woodhead, A. H. Interaction of alcohols with silicon tetrachloride J. Chem. Soc. 1951, 519-522
35. Miner, C. S., Jr.; Bryan, L. A.; Holysz, R. P., Jr.; Pedlow, G. W., Jr. tert -Alkoxyaminosilanes Ind. Eng. Chem. 1947, 39, 1368-1371
36. Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. Estimation of aqueous solubility of chemical compounds using E-state indices J. Chem. Inf. Comput. Sci. 2001, 41, 1488-1493
37. Tetko, I. V.; Gasteiger, J.; Todeschini, R.; Mauri, A.; Livingstone, D.; Ertl, P.; Palyulin, V. A.; Radchenko, E. V.; Zefirov, N. S.; Makarenko, A. S.; Tanchuk, V. Y.; Prokopenko, V. V. Virtual computational chemistry laboratory-design and description J. Comput.-Aided Mol. Des. 2005, 19, 453-463
38. 29Si) NMR spectroscopy J. Non-Cryst. Solids 1986, 91, 402-415
39. Chaudhary, A. G.; Rimoldi, J. M..; Kingston, D. G. I. Modified Taxols. 10. Preparation of 7-deoxytaxol, a highly bioactive taxol derivative, and an interconversion of Taxol and 7-epi-Taxol J. Org. Chem. 1993, 58, 3798-3799
40. Shahani, K.; Swaminathan, S. K.; Freeman, D.; Blum, A.; Ma, L.; Panyam, J. Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention Cancer Res. 2010, 70, 4443-4452